References
- Mann JR, Zhang Y, McDermott S, et al. Racial and ethnic differences in timing of diagnosis and clinical services received in Duchenne muscular dystrophy. Neuroepidemiology. 2023;57(2):90–99. doi: 10.1159/000528962
- Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1): BioMed Central Ltd. doi: 10.1186/s13023-017-0631-3
- Duan D, Goemans N, Takeda S, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1). doi: 10.1038/s41572-021-00248-3
- Kariyawasam D, D’Silva A, Mowat D, et al. Incidence of Duchenne muscular dystrophy in the modern era; an Australian study. Eur J Hum Genet. 2022;30(12):1398–1404. doi: 10.1038/s41431-022-01138-2
- Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251–267. doi: 10.1016/S1474-4422(18)30024-3
- Elangkovan N, Dickson G, Jaiswal J, et al. Gene therapy for Duchenne muscular dystrophy. J Neuromuscul Dis. 2021;8(s2):S303–S316. doi: 10.3233/JND-210678
- Hoffman EP, Fischbeck KH, Brown RH, et al. Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N Engl J Med. 1988;318(21):1363–1368. doi: 10.1056/NEJM198805263182104
- Tulangekar A, Sztal TE. Inflammation in Duchenne muscular dystrophy–exploring the role of neutrophils in muscle damage and regeneration. Biomedicines. 2021 9;9(10):1366. doi: 10.3390/biomedicines9101366
- Gao QQ, McNally EM. The dystrophin complex: structure, function, and implications for therapy. Compr Physiol. 2015;5:1223–1239.
- Wilcox DE, Cooke A, Coigan J, et al. Duchenne muscular dystrophy due to familial Xp21 deletion detectable by DNA analysis and flow cytometry. Hum Genet. 1986;73(2):175–180. doi: 10.1007/BF00291610
- Van Deutekom JCT, Van Ommen GJB. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet. 2003;4(10):774–783. doi: 10.1038/nrg1180
- Evans SR. Fundamentals of clinical trial design. J Exp Stroke Transl Med. 2010;3(1):19–27. doi: 10.6030/1939-067X-3.1.19
- Rossoni C, Bardet A, Geoerger B, et al. Sequential or combined designs for phase I/II clinical trials? A simulation study. Clin Trial. 2019;16(6):635–644. doi: 10.1177/1740774519872702
- Purna Singh A, Shahapur PR, Vadakedath S, et al. Research question, objectives, and endpoints in clinical and oncological research: a comprehensive review. Cureus. 2022. doi: 10.7759/cureus.29575
- Servais L, Yen K, Guridi M, et al. Stride velocity 95th centile: insights into gaining regulatory qualification of the first wearable-derived digital endpoint for use in Duchenne muscular dystrophy trials. J Neuromuscul Dis. 2022;9(2):335–346. doi: 10.3233/JND-210743
- Straub V, Mercuri E, Aartsma-Rus A. Report on the workshop: meaningful outcome measures for Duchenne muscular dystrophy, London, UK, 30–31 January 2017. Neuro Disord. 2018;28(8):690–701. doi: 10.1016/j.nmd.2018.05.013
- Nicholson LV, Johnson MA, Bushby KM, et al. Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. Arch Dis Child. 1993;68:632–636. doi: 10.1136/adc.68.5.632
- Zhang S, Liang F, Tannock I. Use and misuse of common terminology criteria for adverse events in cancer clinical trials. BMC Cancer. 2016;16(1):392. doi: 10.1186/s12885-016-2408-9
- Brogna C, Coratti G, Pane M, et al. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS One. 2019;14(6):e0218683. doi: 10.1371/journal.pone.0218683
- Arora H, Willcocks RJ, Lott DJ, et al. Longitudinal timed function tests in Duchenne muscular dystrophy: imaging DMD cohort natural history. Muscle Nerve. 2018;58(5):631–638. doi: 10.1002/mus.26161
- Broomfield J, Hill M, Guglieri M, et al. Life expectancy in Duchenne muscular dystrophy. Neurology. 2021;97(23):E2304–E2314. doi: 10.1212/WNL.0000000000012910
- Landfeldt E, Thompson R, Sejersen T, et al. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(7):643–653. doi: 10.1007/s10654-020-00613-8
- Angelini C, Peterle E. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy. Acta Myol. 2012;31:9–15.
- Eser G, Topaloğlu H. Current outline of exon skipping trials in Duchenne muscular dystrophy. Genes (Basel). 2022;13(7):1241. MDPI. doi: 10.3390/genes13071241
- Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673–694. doi: 10.1038/s41573-020-0075-7
- Nakamura A, Fueki N, Shiba N, et al. Deletion of exons 3−9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy. J Hum Genet. 2016;61(7):663–667. doi: 10.1038/jhg.2016.28
- Nakamura A, Shiba N, Miyazaki D, et al. Comparison of the phenotypes of patients harboring in-frame deletions starting at exon 45 in the Duchenne muscular dystrophy gene indicates potential for the development of exon skipping therapy. J Hum Genet. 2017;62(4):459–463. doi: 10.1038/jhg.2016.152
- Shirley M. Casimersen: first approval. Drugs. 2021;81:875–879. doi: 10.1007/s40265-021-01512-2
- Syed YY. Eteplirsen: First global approval. Drugs. 2016;76:1699–1704. doi: 10.1007/s40265-016-0657-1
- Heo Y-A. Golodirsen: First approval. Drugs. 2020;80:329–333. doi: 10.1007/s40265-020-01267-2
- Dhillon S. Viltolarsen: First approval. Drugs. 2020;80(10):1027–1031. doi: 10.1007/s40265-020-01339-3
- Dyne Therapeutics. Dyne therapeutics receives FDA fast track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy. Dyne Therapeutics [Internet]. 2022 Oct 31 [cited 2023 Aug 12]; Available from: https://investors.dyne-tx.com/news-releases/news-release-details/dyne-therapeutics-receives-fda-fast-track-designation-dyne-251
- Delivering on the RNA Revolution [internet]. Avidity Biosciences. 2023 [cited 2023 Aug 1]. Available from: https://www.aviditybiosciences.com/pipeline/dmd/
- Aartsma-Rus A, Corey DR. The 10th oligonucleotide therapy approved: golodirsen for Duchenne muscular dystrophy. Nucleic Acid Ther. 2020;30(2):67–70. doi: 10.1089/nat.2020.0845
- Fàbrega C, Aviñó A, Navarro N, et al. Lipid and peptide-oligonucleotide conjugates for therapeutic purposes: from simple hybrids to complex multifunctional assemblies. Pharmaceutics. 2023;15(2):320. doi: 10.3390/pharmaceutics15020320
- Aartsma-Rus A, De Waele L, Houwen-Opstal S, et al. The dilemma of choice for Duchenne patients eligible for exon 51 skipping the European experience. J Neuromuscul Dis. 2023;10(3):315–325. doi: 10.3233/JND-221648
- McClorey G, Banerjee S. Cell-penetrating peptides to enhance delivery of oligonucleotide-based therapeutics. Biomedicines. 2018;6(2):51. doi: 10.3390/biomedicines6020051
- PepGen. PepGen reports positive data from phase 1 trial of PGN-EDO51 for the treatment of Duchenne muscular dystrophy. Boston: PepGen; 2022.
- Holland A, Godfrey C, Lonkar P, et al. PGN-EDO51: preclinical data supporting the development of an enhanced delivery oligonucleotide (EDO) for the treatment of Duchenne muscular dystrophy (DMD) (P3-8.002). Neurology. 2023;100(17_supplement_2):4074. doi: 10.1212/WNL.0000000000203724
- Mellion M, Larkindale J, Lonkar P, et al. PGN-EDO51, an enhanced delivery oligonucleotide (EDO) for the treatment of Duchenne muscular dystrophy (DMD): results of a phase 1 study in healthy volunteers. American Academy of Neurology 2023 Annual Meeting [Internet]. American Academy of Neurology; 2023 [cited 2023 Aug 25]. Available from: https://www.aan.com/MSA/Public/Events/AbstractDetails/54382
- PepGen. PepGen announces clearance by health Canada of CTA for PGN-EDO51 to begin the phase 2 clinical trial, CONNECT1-EDO51, for the treatment of Duchenne muscular dystrophy. BioSpace. [cited 2024 Feb 05]. Available from: https://investors.pepgen.com/news-releases/news-release-details/pepgen-announces-clearance-health-canada-cta-pgn-edo51-begin
- Sheikh O, Yokota T. Pharmacology and toxicology of eteplirsen and SRP-5051 for DMD exon 51 skipping: an update. Arch Toxicol. 2022;96(1):1–9. doi: 10.1007/s00204-021-03184-z
- Sarepta Therapeutics. Sarepta therapeutics announces that FDA has lifted its clinical hold on SRP-5051 for the treatment of Duchenne muscular dystrophy. Globe Newswire [Internet]. 2022 Sep [cited 2023 Aug 12]; Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-has-lifted-its-clinical-hold
- Sahni A, Qian Z, Pei D. Cell-penetrating peptides escape the endosome by inducing vesicle budding and collapse. ACS Chem Biol. 2020;15(9):2485–2492. doi: 10.1021/acschembio.0c00478
- Dougherty PG, Sahni A, Pei D. Understanding cell penetration of cyclic peptides. Chem Rev. 2019;119(17):10241–10287. doi: 10.1021/acs.chemrev.9b00008
- Qian Z, Martyna A, Hard RL, et al. Discovery and mechanism of highly efficient cyclic cell-penetrating peptides. Biochemistry. 2016;55(18):2601–2612. doi: 10.1021/acs.biochem.6b00226
- Wilton-Clark H, Yokota T. Recent trends in antisense therapies for Duchenne muscular dystrophy. Pharmaceutics. 2023;15(3):778. doi: 10.3390/pharmaceutics15030778
- Keown A FDA places clinical hold on entrada’s IND for Duchenne muscular dystrophy [internet]. Biospace. 2022 [cited 2023 Oct 21]. Available from: https://www.biospace.com/article/fda-places-clinical-hold-on-entrada-s-ind-for-duchenne-muscular-dystrophy-/
- Entrada therapeutics. Entrada therapeutics receives authorization in the United Kingdom to initiate phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy [internet]. CureDuchenne. 2023 [cited 2023 Oct 21]. Available from: https://cureduchenne.org/research/entrada-dmd/
- MacDonald K. Entrada therapeutics announces first participant dosed in its phase 1 clinical trial of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy [internet]. Biospace. 2023 [cited 2023 Oct 21]. Available from: https://www.biospace.com/article/releases/entrada-therapeutics-announces-first-participant-dosed-in-its-phase-1-clinical-trial-of-entr-601-44-for-the-potential-treatment-of-duchenne-muscular-dystrophy/
- Komaki H, Takeshita E, Kunitake K, et al. P.123 a phase I/II study of NS-089/NCNP-02, Exon 44 skipping drug, in patients with Duchenne muscular dystrophy. Neuro Disord. 2022;32:S99–S100. doi: 10.1016/j.nmd.2022.07.239
- Nippon Shinyaku Co. Ltd. FDA grants breakthrough therapy designation to NS-089/NCNP-02 for the treatment of Duchenne muscular dystrophy. Nippon Shinyaku Co, Ltd [Internet]. [cited 2023 Jul 28]. Available from: https://www.ncnp.go.jp/topics/2022/20220317e.html
- Camusat A. SQY therapeutics – the “avance 1” clinical trial – Duchenne muscular dystrophy [internet]. SQY Therapeutics. 2023 [cited 2023 Aug 7]. Available from: https://sqy-therapeutics.com/en/sqy-therapeutics-avance-1-duchenne-muscular-dystrophy-home/.
- Meglio M. Duchenne Agent WVE-N531 Shows Targeted Exon Skipping in Phase 1/2 Study. Neurology Live [Internet]. 2022 Dec 20 [cited 2023 Aug 12]. Available from: https://www.neurologylive.com/view/duchenne-agent-wve-n531-shows-targeted-exon-skipping-phase-1-2-study
- Gushchina LV, Frair EC, Rohan N, et al. Lack of toxicity in nonhuman primates receiving clinically relevant doses of an AAV9.U7snRNA vector designed to induce DMD exon 2 skipping. Hum Gene Ther. 2021;32:882–894. doi: 10.1089/hum.2020.286
- Happi Mbakam C, Lamothe G, Tremblay JP. Therapeutic strategies for dystrophin replacement in duchenne muscular dystrophy. Front Med. 2022;9. doi: 10.3389/fmed.2022.859930
- Waldrop D, Lawlor D, Vetter TM, et al. 3 expression of apparent full-length dystrophin in skeletal muscle in a first-in-human gene therapy trial using the scAAV9.U7-ACCA vector. Neuro Disord. 2020;30:S166–S167. doi: 10.1016/j.nmd.2020.09.008
- Parent Project Muscular Dystrophy. Astellas gene therapies announces plans to discontinue development of duchenne gene therapy programs [Internet]. Parent Project Muscular Dystrophy. 2022 [cited 2023 Oct 21]. Available from: https://www.parentprojectmd.org/astellas-gene-therapies-announces-plans-to-discontinue-development-of-duchenne-gene-therapy-programs/
- Bönnemann CG, Belluscio BA, Braun S, et al. Dystrophin immunity after gene therapy for Duchenne’s muscular dystrophy. N Engl J Med. 2023;388(24):2294–2296. doi: 10.1056/NEJMc2212912
- Mendell JR, Proud C, Zaidman CM, et al. Practical considerations for delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy. Pediatr Neurol. 2024. doi: 10.1016/j.pediatrneurol.2024.01.003
- Lek A, Wong B, Keeler A, et al. Death after high-dose rAAV9 gene therapy in a patient with Duchenne’s muscular dystrophy. N Engl J Med. 2023;389(13):1203–1210. doi: 10.1056/NEJMoa2307798
- Duan D. Dystrophin gene replacement and gene repair therapy for Duchenne muscular dystrophy in 2016: an interview. Hum Gene Ther Clin Dev. 2016;27(1):9–18. doi: 10.1089/humc.2016.001
- Danos O. In the pipeline: pre-clinical gene therapy- REGENXBIO - RGX-202: an investigational gene therapy for Duchenne muscular dystrophy (DMD). Parent Project Muscular Dystrophy 2021 Virtual Annual Conference [Internet]. 2021 [cited 2023 Aug 20]. Available from: https://www.parentprojectmd.org/drug-development-pipeline/rgx-202/
- Binks M. Pfizer presents at the parent project muscular dystrophy 2019 annual conference. Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]. 2019 [cited 2023 Aug 20]. Available from: http://www.parentprojectmd.org/drug-development-pipeline/pf-06939926-mini-dystrophin-gene-therapy/
- Laforet G. Solid biosciences presents at the parent project muscular dystrophy 2019 annual conference. Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]. Orlando, FLorida: Parent Project Muscular Dystrophy; 2019 [cited 2023 Aug 20]. Available from: https://www.parentprojectmd.org/drug-development-pipeline/pf-06939926-mini-dystrophin-gene-therapy/
- Ingram D. Sarepta presents at the parent project muscular dystrophy 2019 annual conference. Parent Project Muscular Dystrophy 2019 Annual Conference [Internet]. 2019 [cited 2023 Aug 20]. Available from: https://www.parent.projectmd.org/drug-development-pipeline/pf-06939926-mini-dystrophin-gene-therapy/
- Sarepta Therapeutics. Sarepta Therapeutics announces topline results from EMBARK, a global pivotal study of ELEVIDYS gene therapy for Duchenne muscular dystrophy. 2023 Oct 30 [cited 2023 Dec 28]. Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-topline-results-embark-global-0
- REGENXBIO. Therapeutic pipeline: RGX-202 for Duchenne. REGENXBIO [Internet]. 2023 [cited 2023 Aug 12]. Available from: https://www.regenxbio.com/therapeutic-programs/rgx-202/
- Pfizer. Pfizer presents initial clinical data on phase 1b gene therapy study for Duchenne muscular dystrophy (DMD). Orlando, Florida: Pfizer; 2019.
- Belluscio B, Beaverson K, Garnier N, et al. Safety and efficacy of PF-06939926 gene therapy in boys with Duchenne muscular dystrophy: update on data from the phase 1b study. MDA Clinical and Scientific Conference 2021; 2021 [cited 2023 Aug 12]. p. 77. Available from: https://www.mdaconference.org/abstract-library/safety-and-efficacy-of-pf-06939926-gene-therapy-in-boys-with-duchenne-muscular-dystrophy-update-on-data-from-the-phase-1b-study/
- Johnson V. PF-06939926 continues to show safety and efficacy in Duchenne muscular dystrophy. Neurology Live [Internet]. 2021 Apr 21 [cited 2023 Aug 13]; Available from: https://www.neurologylive.com/view/pf-06939926-safe-efficacious-dmd
- Reinhard A. Patient death reported in phase 1b mini-dystrophin gene therapy trial in DMD. Neurology Live. 2021. [cited 2024 Feb 05]. Available from: https://www.neurologylive.com/view/patient-death-reported-phase-1b-mini-dystrophin-gene-therapy-trial-dmd
- Philippidis A. Food and drug administration lifts clinical hold on pfizer Duchenne muscular dystrophy gene therapy linked to patient death. Hum Gene Ther. 2022;33(11–12):573–576. doi: 10.1089/hum.2022.29211.bfs
- Johnson V. High dose fordadistrogene movaparvovec improves NSAA, muscle volume in patients with DMD. CGT Live. 2023 May 23;
- Shieh PB, Butterfield RJ, Munotni F, et al. Two-year clinical outcomes with fordadistrogene movaparvovec for Duchenne muscular dystrophy (DMD) and contextualization with external controls. American Society of Gene & Cell Therapy (ASGCT) Annual Conference. Los Angeles, California; 2023.
- Shieh PB. Emerging strategies in the treatment of Duchenne muscular dystrophy. Neurotherapeutics. 2018;15(4):840–848. doi: 10.1007/s13311-018-00687-z
- Solid Biosciences. Solid biosciences reports fourth quarter and full-year 2021 financial results and 2-year efficacy and safety data from the ongoing phase I/II IGNITE DMD clinical trial of SGT-001. Solid Biosciences. 2021;2021(4):2–3. doi: 10.1016/j.fopow.2021.03.008
- Solid Biosciences. Solid biosciences announces updated corporate strategy to develop SGT-001 and SGT-003 pipeline programs for patients with duchenne muscular dystrophy. Global Newswire. 2022 Apr 22;
- Zygmunt DA, Xu R, Jia Y, et al. rAavrh74.Mck.galgt2 demonstrates safety and widespread muscle glycosylation after intravenous delivery in C57BL/6J mice. Mol Ther Methods Clin Dev. 2019;15:305–319. doi: 10.1016/j.omtm.2019.10.005
- Cramer ML, Xu R, Martin PT. Soluble heparin binding epidermal growth factor-like growth factor is a regulator of GALGT2 expression and GALGT2 -dependent muscle and neuromuscular phenotypes. Mol Cell Biol. 2019;39(14):39. doi: 10.1128/MCB.00140-19
- Genethon. Genethon announces first patient dosed in clinical trial of investigational gene therapy GNT 0004 for Duchenne muscular dystrophy [internet]. Genethon. 2021 [cited 2023 Oct 21]. Available from: https://www.genethon.com/genethon-announces-first-patient-dosed-in-clinical-trial-of-investigational-gene-therapy-gnt-0004-for-duchenne-muscular-dystrophy/
- Genethon. Duchenne muscular dystrophy - our pipeline [Internet]. Genethon. 2023 [cited 2023 Oct 21]. Available from: https://www.genethon.com/our-pipeline/duchenne-muscular-dystrophy/
- Russell AJ, DuVall M, Barthel B, et al. Modulating fast skeletal muscle contraction protects skeletal muscle in animal models of Duchenne muscular dystrophy. J Clin Investig. 2023;133(10). doi: 10.1172/JCI153837
- Edgewise Therapeutics. Corporate presentation: August 2023 [internet]. 2023 [cited 2023 Aug 22]. Available from: https://s29.q4cdn.com/148823924/files/doc_presentations/2023/Aug/03/ewtx-corporate-presentation_august-2023_vfinal.pdf
- Sung DK, Kim H, Park SE, et al. A new method of myostatin inhibition in mice via oral administration of Lactobacillus casei expressing modified myostatin protein, BLS-M22. Int J Mol Sci. 2022;23(16):9059. doi: 10.3390/ijms23169059
- Grover N. Another myostatin program combusts, but acceleron has plenty in the pipeline. Endpoints News [Internet]. 2020 Mar 10 [cited 2023 Oct 21]; Available from: https://endpts.com/another-myostatin-program-combusts-but-acceleron-has-plenty-in-the-pipeline/
- Keown A. Roche Terminates myostatin inhibitor for DMD one year after pfizer did the same [Internet]. Biospace. 2019 [cited 2023 Oct 21]. Available from: https://www.biospace.com/article/roche-terminates-myostatin-inhibitor-for-dmd-one-year-after-pfizer-did-the-same/
- Schreiner G. Understanding the potential of Epicatechin. Parent project muscular dystrophy [internet]. Parent Project Muscular Dystrophy; 2015 [cited 2023 Aug 21]. Available from: https://www.parentprojectmd.org/aiovg_videos/understanding-the-potential-of-epicatechin-december-2015/
- Baranovskii DS, Klabukov ID, Arguchinskaya NV, et al. Adverse events, side effects and complications in mesenchymal stromal cell-based therapies. Stem Cell Investig. 2022;9:7–7. doi: 10.21037/sci-2022-025
- Lee J, Kim M, Jeon H, et al. An open-label, dose-escalation, phase 1a study to evaluate safety, tolerability, and exploratory efficacy of intravenous injection of allogenic early-passage mesenchymal stem cells (MSCs), derived from Wharton’s jelly in the umbilical cord, in patients with Duchenne muscular dystrophy. American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting [Internet]. 2023 [cited 2023 Aug 22]. Available from: https://www.cgtlive.com/view/allogeneic-msc-therapy-demonstrates-safety-patients-duchenne-muscular-dystrophy
- ENCell. Next generation stem cell therapeutics [internet]. ENCell Co., Ltd. 2023 [cited 2023 Aug 22]. Available from: http://encellinc.com/?module=Html&action=SiteCompEn&sSubNo=8
- McDonald CM, Marbán E, Hendrix S, et al. Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2022;399(10329):1049–1058. doi: 10.1016/S0140-6736(22)00012-5
- Matthews E, Brassington R, Kuntzer T, et al. Corticosteroids for the treatment of Duchenne muscular dystrophy. Cochrane Database Syst Rev. 2016;2016. doi: 10.1002/14651858.CD003725.pub4
- Chakraborty A, Tannenbaum S, Rordorf C, et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet. 2012;51(6):e1–e18. doi: 10.2165/11599820-000000000-00000
- Savino AM, Sarno J, Trentin L, et al. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Leukemia. 2017;31(11):2365–2375. doi: 10.1038/leu.2017.93
- Miller D. Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections. Clin Ophthalmol. 2008;77:77. doi: 10.2147/OPTH.S1666
- Bettica P. Italfarmaco group announces positive topline data from phase 3 trial showing beneficial effect of givinostat in patients with Duchenne muscular dystrophy. Annual Parent Project Muscular Dystrophy Conference 2022 [Internet]. Businesswire; 2022 [cited 2023 Oct 18]. Available from: https://www.businesswire.com/news/home/20220625005001/en/Italfarmaco-Group-Announces-Positive-Topline-Data-from-Phase-3-Trial-Showing-Beneficial-Effect-of-Givinostat-in-Patients-with-Duchenne-Muscular-Dystrophy
- Previtali SC, Gidaro T, Díaz-Manera J, et al. Rimeporide as a first- in-class NHE-1 inhibitor: results of a phase Ib trial in young patients with Duchenne muscular dystrophy. Pharmacol Res. 2020;159:159. doi: 10.1016/j.phrs.2020.104999
- EspeRare. FDA has granted rare pediatric disease designation to Rimeporide. Geneva, Switzerland: EspeRare; 2020. [cited 2024 Feb 05]. Available from: https://esperare.org/en/news/archive/202009
- Paquin RS, Fischer R, Mansfield C, et al. Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best–worst scaling experiment in caregivers and adult patients. Orphanet J Rare Dis. 2019;14(1):14. doi: 10.1186/s13023-019-1069-6
- Markati T, De Waele L, Schara-Schmidt U, et al. Lessons learned from discontinued clinical developments in Duchenne muscular dystrophy. Front Pharmacol. 2021;12:12. doi: 10.3389/fphar.2021.735912
- Mah J. Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat. 2016;Volume 12:1795–1807. doi: 10.2147/NDT.S93873
- FDA. FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy. US Food and Drug Administration [Internet]. 2023 Jun 22 [cited 2023 Dec 31]; Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-treatment-certain-patients-duchenne-muscular-dystrophy
- McCain J. The future of gene therapy. Biotechnol Healthc. 2005;2:52–60.
- Reardon S. ‘It’s a vote for hope’: first gene therapy for muscular dystrophy nears approval, but will it work? Nature. 2023 Jun 2;618(7965):451–453. doi: 10.1038/d41586-023-01799-z
- Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13. doi: 10.3389/fimmu.2022.975803
- FDA. Duchenne muscular dystrophy and related dystrophinopathies: developing drugs for treatment guidance for industry [Internet]. 2018. Available from: https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htmand/orhttps://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm